The Effect of Quitting Smoking on Costs and Healthcare Utilization in Patients with Chronic Obstructive Pulmonary Disease: A Comparison of Current Smokers Versus Ex-Smokers in Routine Clinical Practice

Sicras‐Mainar, Antoni; Rejas‐Gutiérrez, Javier; Navarro‐Artieda, Ruth; Ibáñez-Nolla, Jordi

doi:10.1007/s00408-014-9592-7

Cited by 18 publications

(19 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These annual average cost savings were different depending on the population analyzed: €651 for t2-DM, €200 for patients with CVD and €779 (40- 11 €1,345 (+70 years) for COPD [20][21][22] ( table 1 ). This is then added up over the complete 5-year follow-up period for the analysis.…”

Section: Discussionmentioning

confidence: 99%

“…Moreover, smoking cessation has been shown to be associated with substantial savings for the SNHS, particularly in the publically funded healthcare costs for these health conditions, with an average annual per patient saving varying between €1,345 for COPD patients to €200 in CVD patients per year [20][21][22] . However, smoking-cessation treatments are not funded in those subjects who would like to quit smoking.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective

Cedillo¹,

Sicras‐Mainar²,

Jiménez-Ruíz³

et al. 2016

Eur Addict Res

Self Cite

View full text Add to dashboard Cite

Aims: The study aimed to assess the budgetary impact (BI) of reimbursing varenicline in patients with chronic obstructive pulmonary disease (COPD), type-2 diabetes mellitus (t2-DM) or cardiovascular diseases (CVD). Methods: The BI was estimated comparing the current non-reimbursed scenario versus a projected reimbursed scenario using the Spanish National Health System (SNHS) perspective. A hybrid model was developed using epidemiological data and Markov chains to estimate smoking cessation rates with varenicline during a 5-year horizon. Costs of cessation were considered in the reimbursement scenario only. Efficacy, expressed as a 1-year continuous abstinence rate, was derived from clinical trials. Cost savings due to smoking cessation were extracted from local cost-of-illness studies. Results are shown as incremental cost savings. Univariate sensitivity analysis was also applied. Results: A total of 68,684 patients stopped smoking in the reimbursed scenario compared with 15,208 without reimbursement. In the reimbursed scenario, total savings accounted for €36.3 million, showing 14.6 million accumulated additional savings compared with the scenario without reimbursement. Sensitivity analyses showed results to be robust with monetary savings starting in the third year of modeling. Conclusion: Reimbursement of varenicline in smoking cessation is a cost-effective health policy in the SNHS in COPD, t2-DM or CVD, and could produce cost savings starting in the third year of implementation.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective

Cedillo¹,

Sicras‐Mainar²,

Jiménez-Ruíz³

et al. 2016

Eur Addict Res

Self Cite

View full text Add to dashboard Cite

show abstract

“…As for the estimate of the savings resulting from the cessations, this was done separately, for each disease branch 1 . The average annual cost per COPD patient was assumed to be € 2,723.7 [19]; the estimate for the smoking and non-smoking population was carried out by adopting the savings ratio collected by Sicras-Mainar [6] from a cohort of Spanish patients with COPD specifically treated to promote smoking cessation, which highlighted a cost of € 3.775,4 per smoking patient and € 2,382.4 per no longer smoking patient, with an average annual saving per capita resulting from the cessation of € 1,393.0. Through a similar procedure, patients with diabetes are assumed to have a mean annual cost per patient of € 2,898.0 [20].…”

Section: Costsmentioning

confidence: 99%

“…The WHO also estimates that about half of regular smokers are destined to die prematurely, due to tobacco consumption [1], and similar values also emerge from studies conducted on individual Countries [2]. Tobacco consumption increases the risk of cardiovascular (CVD) [3,4] and bronchopulmonary diseases (COPD -chronic obstructive pulmonary disease) [5,6], as well as being the main cause of some types of cancer. It is also a risk factor for several chronic conditions, including type 2 diabetes [7].…”

Section: Introductionmentioning

confidence: 95%

See 1 more Smart Citation

Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

Spandonaro

Mancusi²,

Polistena

2017

View full text Add to dashboard Cite

INTRODUCTION: The promotion of smoking cessation is a worldwide Public Health priority. OBJECTIVE: To estimate the budget impact on the Italian National Health Service (NHS) of the access to reimbursement of varenicline for the treatment of high risk patients with bronchopulmonary, diabetic and cardiovascular diseases. METHODS: A closed-group Markov model was developed in order to compare the costs incurred by the NHS to promote smoking cessation with cessation-related savings, using an alternative scenario in which aids to cessation are not reimbursed by the NHS. The analysis was conducted over a 5-year time horizon, in the perspective of the Italian NHS. Efficacy was expressed in terms of smoke abstinence for at least one year, and data was derived from clinical trials; the savings associated with smoking cessation were derived from cost-of-illness studies. RESULTS: The results show how costs would concentrate in the first year: they are estimated at € 200.6 million, of which € 162.4 million for drug therapy and € 38.2 million for counseling. Average annual savings over the first five years are estimated at € 77.7 million, with a cumulative net impact at 5 years of € -188.0 million (cost-saving). The analysis appears to be robust: sensitivity analyses show that the covering of initial costs occurs in any case between the third and fourth year, and that the treatment remains cost-saving at 5 years. CONCLUSIONS: The financial impact on the Italian NHS of the reimbursement of varenicline for the treatment of high risk smoking population would be a sustainable healthcare policy, resulting in cost savings starting from the fourth year.

show abstract

Cost–benefit analysis of funding smoking cessation before surgery

Jiménez-Ruíz

Martín

Alsina-Restoy

et al. 2020

British Journal of Surgery

View full text Add to dashboard Cite

Background Smoking at the time of surgery is associated with postoperative complications. Quitting smoking before surgery is linked to fewer complications during the hospital stay. This work analysed whether a smoking cessation intervention before surgery is economically worthwhile when funded by the National Health System (NHS) in Spain. Methods The economic analysis considered costs and benefits of the intervention to the NHS for the year 2016. The population who would benefit comprised adult smokers who were ready to quit and for whom surgery requiring admission to hospital was planned. The intervention, a combination of medical counselling and use of a smoking cessation drug which should occur 12 weeks before surgery, considered one attempt only to quit smoking. Benefits were costs avoided by averting postoperative complications if cessation was successful. The analysis compared the net economic outcome (benefit minus cost of intervention) and the return on investment, for intervention funded by the NHS versus the current situation without funding. Results Smoking cessation increased by 21·7 per cent with funding; the rate was 32·5 per cent when funded versus 10·7 per cent without funding, producing 9611 extra quitters. The cost per averted smoker was €1753 with a benefit of €503, achieving a net economic benefit of €4·8 million per year. Given the annual cost of the intervention (€17·4 million, of which €5·6 million (32·5 per cent) represents drugs), the return on investment was 28·7 per cent annually, equivalent to €1·29 per €1 of investment. Conclusion From the perspective of the Spanish NHS, the benefit of funding smoking cessation before surgery, in terms of healthcare cost savings, appears to greatly outweigh the costs.

show abstract

The Effect of Quitting Smoking on Costs and Healthcare Utilization in Patients with Chronic Obstructive Pulmonary Disease: A Comparison of Current Smokers Versus Ex-Smokers in Routine Clinical Practice

Cited by 18 publications

References 38 publications

Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective

Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective

Varenicline treatment for smoking cessation in high risk patients: a budget impact analysis

Cost–benefit analysis of funding smoking cessation before surgery

Contact Info

Product

Resources

About